Contact this trialFirst, we need to learn more about you.
Alkylating agents
Sotorasib + Chemotherapy for Lung Cancer
Recruiting1 awardPhase 2
New York, New York
This trial is testing a new way to treat non-squamous NSCLC that has a KRAS p.G12C mutation. The new treatment is neoadjuvant sotorasib in combination with cisplatin (or carboplatin) and pemetrexed chemotherapy. The goal is to see if this new treatment is safe and results in an improved MPR rate (meaning the tumor shrinks) compared to the historical control MPR rate for platinum-based chemotherapy alone.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service